Mga Batayang Estadistika
| CIK | 1412067 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cascadian Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| April 9, 2018 |
CASC / Cascadian Therapeutics, Inc. / Baupost Group LLC/MA - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Cascadian Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14740B606 (CUSIP Number) March 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| March 22, 2018 |
CASC / Cascadian Therapeutics, Inc. 15-12B 15-12B 1 d539976d1512b.htm 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-33882 Cascadian Therapeutics, Inc. (Ex |
|
| March 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Cascadian Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 682324108 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 (Name |
|
| March 9, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2018 CASCADIAN THERAPEUTICS, INC. |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. POS462B POS462B As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. S-8 POS S-8 POS 1 d497346ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. 333-162640 Registration No. 333-167302 Registration No. 333-172814 Registration No. 333-180025 Registration No. 333-187257 Registration No. 333-196581 Registration No. 333-202647 Registration No. 333-212201 Registration No. 333-218599 UNITED STATES SECURITIES AND EXCHANGE COMM |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. S-8 POS S-8 POS 1 d497346ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. 333-162640 Registration No. 333-167302 Registration No. 333-172814 Registration No. 333-180025 Registration No. 333-187257 Registration No. 333-196581 Registration No. 333-202647 Registration No. 333-212201 Registration No. 333-218599 UNITED STATES SECURITIES AND EXCHANGE COMM |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. S-8 POS S-8 POS 1 d497346ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. 333-162640 Registration No. 333-167302 Registration No. 333-172814 Registration No. 333-180025 Registration No. 333-187257 Registration No. 333-196581 Registration No. 333-202647 Registration No. 333-212201 Registration No. 333-218599 UNITED STATES SECURITIES AND EXCHANGE COMM |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on March 9, 2018 Registration No. |
|
| March 9, 2018 |
CASC / Cascadian Therapeutics, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9/A (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) CASCADIAN THERAPEUTICS, INC. (Name of Subject Company) CASCADIAN THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title |
|
| March 9, 2018 |
Seattle Genetics Completes Tender Offer for All Shares of Cascadian Therapeutics EX-99.(a)(5)(ii) Exhibit (a)(5)(ii) Seattle Genetics Completes Tender Offer for All Shares of Cascadian Therapeutics BOTHELL WA – March 9, 2018 – Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the expiration of the tender offer (the “Offer”) by a wholly owned subsidiary, “Merger Sub”, for all of the shares of common stock of Cascadian Therapeutics, Inc. (Nasdaq:CASC), for a price of $10.00 p |
|
| March 9, 2018 |
SGEN / Seattle Genetics, Inc. AMENDMENT NO. 2 TO SC TO-T AMENDMENT NO. 2 TO SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) CASCADIAN THERAPEUTICS, INC. (Name of Subject Company (Issuer)) VALLEY ACQUISITION SUB, INC. (Offeror) SEATTLE GENETICS, INC. (Parent of Offeror) (Names |
|
| March 8, 2018 |
CASC / Cascadian Therapeutics, Inc. 10-K (Annual Report) 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 8, 2018 |
Sublease between CTI Biopharma, Corp. and Cascadian Therapeutics, Inc., dated December 4, 2017 EX-10.18 Exhibit 10.18 3101 WESTERN AVENUE SEATTLE, WASHINGTON SUBLEASE by and between CTI BIOPHARMA, CORP., a Washington corporation as SUBLANDLORD and CASCADIAN THERAPEUTICS, INC., a Delaware corporation as SUBTENANT TABLE OF CONTENTS Page 1. Sublease 3 2. Proposed Subtenant Improvements 4 3. Sublease Term 4 4. Use 5 5. Rent and Additional Charges 6 6. Master Lease Terms 8 7. Maintenance and Rep |
|
| March 8, 2018 |
Subsidiaries of Cascadian Therapeutics, Inc. EX-21.1 EXHIBIT 21.1 SUBSIDIARIES OF CASCADIAN THERAPEUTICS, INC. Name of Subsidiary Jurisdiction of Incorporation Oncothyreon Canada ULC Alberta Biomira Management, Inc. Delaware ProlX Pharmaceuticals Corporation Delaware 0811769 B.C. ULC British Columbia Oncothyreon Luxembourg s.a.r.l. Protocell Therapeutics Inc. Luxembourg Delaware Cascadian Therapeutics (Australia) Pty Ltd Australia |
|
| March 8, 2018 |
EX-10.16 Exhibit 10.16 LEASE TERMINATION AGREEMENT [FOURTH AND VINE] This Lease Termination Agreement (this “Agreement”) is entered into as of the 4th day of December 2017, by and between Selig Holdings Company, a Washington limited liability company (“Landlord”) and Cascadian Therapeutics, Inc., a Delaware corporation (“Tenant”), formerly known as Oncothyreon Inc. R E C I T A L S: A. Landlord and |
|
| March 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cascadian Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 682324108 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 (Name |
|
| February 26, 2018 |
CASC / Cascadian Therapeutics, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) CASCADIAN THERAPEUTICS, INC. (Name of Subject Company) CASCADIAN THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of |
|
| February 16, 2018 |
CASC / Cascadian Therapeutics, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CASCADIAN THERAPEUTICS, INC. (Name of Subject Company) CASCADIAN THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of |
|
| February 16, 2018 |
Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period EX-99.(a)(5)(i) Exhibit (a)(5)(i) Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period BOTHELL WA ? February 16, 2018 ? Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the ?HSR Act?) with respect to Seattle Genetics? proposed acquisition of Cascadian Therapeutics, Inc. (NASDAQ |
|
| February 16, 2018 |
SGEN / Seattle Genetics, Inc. AMENDMENT NO. 1 TO SC TO-T AMENDMENT NO. 1 TO SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) CASCADIAN THERAPEUTICS, INC. (Name of Subject Company (Issuer)) VALLEY ACQUISITION SUB, INC. (Offeror) SEATTLE GENETICS, INC. (Parent of Offeror) (Names |
|
| February 14, 2018 |
CASC / Cascadian Therapeutics, Inc. SC 14D9/A SC 14D9/A 1 d540192dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CASCADIAN THERAPEUTICS, INC. (Name of Subject Company) CASCADIAN THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, par v |
|
| February 14, 2018 |
EX-99.(a)(5)(c) Exhibit (a)(5)(C) Employee FAQs General Questions About the Merger What was announced on January 31, 2018? On January 31, 2018 we announced that we have entered into a definitive merger agreement with Seattle Genetics, Inc. (?Seattle Genetics?) for Seattle Genetics to acquire Cascadian Therapeutics, Inc. (?Cascadian?) at a price of $10.00 per share in an all-cash transaction, a sig |
|
| February 13, 2018 |
CASC / Cascadian Therapeutics, Inc. / Baupost Group LLC/MA - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Cascadian Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14740B606 (CUSIP Number) Calendar Year 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 8, 2018 |
CASC / Cascadian Therapeutics, Inc. SC 14D9 SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 8, 2018 |
EX-99.(A)(1)(IV) 5 d525966dex99a1iv.htm EX-99.(A)(1)(IV) Exhibit (a)(1)(iv) Offer To Purchase For Cash All Outstanding Shares of Common Stock of CASCADIAN THERAPEUTICS, INC. at $10.00 NET PER SHARE IN CASH Pursuant to the Offer to Purchase dated February 8, 2018 by VALLEY ACQUISITION SUB, INC., a wholly owned subsidiary of SEATTLE GENETICS, INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 |
|
| February 8, 2018 |
EX-99.(a)(1)(ii) Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of CASCADIAN THERAPEUTICS, INC. at $10.00 NET PER SHARE IN CASH Pursuant to the Offer to Purchase dated February 8, 2018 by VALLEY ACQUISITION SUB, INC., a wholly owned subsidiary of SEATTLE GENETICS, INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, ON MARCH 9, 2018 (ON |
|
| February 8, 2018 |
EX-99.(d)(2) Exhibit (d)(2) CONFIDENTIALITY AGREEMENT This Confidentiality Agreement (the ?Agreement?), effective as of July 8, 2016 (the ?Effective Date?), is by and between Cascadian Therapeutics, Inc. (the ?Disclosing Party?) and Seattle Genetics, Inc. (the ?Recipient?). WHEREAS, in connection with the Recipient?s consideration of a possible negotiated acquisition of the Disclosing Party by the |
|
| February 8, 2018 |
EX-99.(a)(1)(v) Exhibit (a)(1)(v) Offer To Purchase For Cash All Outstanding Shares of Common Stock of CASCADIAN THERAPEUTICS, INC. at $10.00 Net Per Share In Cash Pursuant to the Offer to Purchase dated February 8, 2018 by VALLEY ACQUISITION SUB, INC., a wholly owned subsidiary of SEATTLE GENETICS, INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, ON MARCH 9, |
|
| February 8, 2018 |
SGEN / Seattle Genetics, Inc. SC TO-T SC TO-T 1 d525966dsctot.htm SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 CASCADIAN THERAPEUTICS, INC. (Name of Subject Company (Issuer)) VALLEY ACQUISITION SUB, INC. (Offeror) SEATTLE GENETICS, INC. (Parent of Offeror) (Names of Filing |
|
| February 8, 2018 |
Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc. EX-99.(a)(1)(vii) Exhibit (a)(1)(vii) Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc. BOTHELL, WA ? February 8, 2018 ? Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc., has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc. (NASDAQ:CASC |
|
| February 8, 2018 |
EX-99.(a)(1)(i) Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of CASCADIAN THERAPEUTICS, INC. at $10.00 Net per Share In Cash by VALLEY ACQUISITION SUB, INC., a wholly owned subsidiary of SEATTLE GENETICS, INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, ON MARCH 9, 2018 (ONE MINUTE AFTER 11:59 P.M., NEW |
|
| February 8, 2018 |
EX-99.(a)(1)(vi) Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase (as defined below) and the related Letter of Transmittal (as defined below) and any amendments or supplements thereto. The Offer is not being made to (and no tenders will |
|
| February 8, 2018 |
EX-99.(a)(1)(iii) Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of CASCADIAN THERAPEUTICS, INC. at $10.00 NET PER SHARE IN CASH Pursuant to the Offer to Purchase dated February 8, 2018 by VALLEY ACQUISITION SUB, INC., a wholly owned subsidiary of SEATTLE GENETICS, INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, ON MAR |
|
| February 7, 2018 |
EX-99.1 Exhibit 99.1 Company: Seattle Genetics Conference Title: 4th Quarter & Year 2017 Call Conference ID: 9278036 Moderator: Meghann Swenson Date: February 6, 2018 Operator: Good day ladies and gentlemen. Welcome to the Seattle Genetics 4th Quarter End Year 2017 Financial Results Conference Call. Today?s call is being recorded. At this time, I?d like to turn the conference over to Peggy Pinksto |
|
| February 7, 2018 |
SGEN / Seattle Genetics, Inc. SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 CASCADIAN THERAPEUTICS, INC. (Name of Subject Company (Issuer)) VALLEY ACQUISITION SUB, INC. a wholly owned subsidiary of SEATTLE GENETICS, INC. (Names of Filing Persons (Offerors)) COMMON STOCK, PA |
|
| February 7, 2018 |
Form of Amendment to Employee Confidentiality, Invention Assignment and Non-Compete Agreements EX-10.2 Exhibit 10.2 FORM OF AMENDMENT TO EMPLOYEE CONFIDENTIALITY, INVENTION ASSIGNMENT AND NON-COMPETE AGREEMENT THIS AMENDMENT TO EMPLOYEE CONFIDENTIALITY, INVENTION ASSIGNMENT AND NON-COMPETE AGREEMENT (this ?Amendment?), dated as of , 2018 (the ?Amendment Date?), is entered into by and between Cascadian Therapeutics, Inc. (the ?Company?) and (?Executive?). WHEREAS, the Company and Executive a |
|
| February 7, 2018 |
Form of Transaction Bonus Agreement. EX-10.5 Exhibit 10.5 TRANSACTION BONUS AGREEMENT THIS TRANSACTION BONUS AGREEMENT dated as of , 2018 (this ?Agreement?) is entered into by and between Cascadian Therapeutics, Inc. (the ?Company?) and (?Service Provider?). ARTICLE 1 TRANSACTION BONUS 1.01 Transaction Bonus. (a) Subject to the terms and conditions set forth in this Agreement, upon a Change in Control, Service Provider shall be entit |
|
| February 7, 2018 |
Amendment to Scott Myers Confidentiality Agreement EX-10.1 2 d536826dex101.htm EX-10.1 Exhibit 10.1 AMENDMENT TO EMPLOYEE INVENTION ASSIGNMENT AND CONFIDENTIALITY AGREEMENT THIS AMENDMENT TO EMPLOYEE INVENTION ASSIGNMENT AND CONFIDENTIALITY AGREEMENT (this “Amendment”), dated as of , 2018 (the “Amendment Date”), is entered into by and between Cascadian Therapeutics, Inc. (the “Company”) and Scott Myers (“Executive”). WHEREAS, the Company and Execu |
|
| February 7, 2018 |
Form of Amendment to Executive Employment Agreements EX-10.4 Exhibit 10.4 FORM OF AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS FORM OF AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this ?Amendment?), dated as of , 2018 (the ?Amendment Date?), is entered into by and between Cascadian Therapeutics, Inc. (the ?Company?) and (?Executive?). WHEREAS, the Company and Executive are parties to that certain Executive Employment Agreement, made effective as |
|
| February 7, 2018 |
8-K 1 d536826d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2018 CASCADIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33882 26-0868560 (State or other jurisdiction |
|
| February 7, 2018 |
Amendment to Scott Myers Confidentiality Agreement. EX-10.3 4 d536826dex103.htm EX-10.3 Exhibit 10.3 AMENDMENT TO OFFER LETTER OF EMPLOYMENT THIS AMENDMENT TO OFFER LETTER OF EMPLOYMENT (this “Amendment”), dated as of , 2018 (the “Amendment Date”), is entered into by and between Cascadian Therapeutics, Inc. (the “Company”) and Scott Myers (“Executive”). WHEREAS, the Company and Executive are parties to that certain Offer Letter of Employment, made |
|
| February 6, 2018 |
CASC / Cascadian Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment casc17a2.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 14740B606 13G Page 1 of 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CASCADIAN THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 14740B606 (CUSIP Number) December 31, 2017 (Date of |
|
| January 31, 2018 |
LinkedIn posting by Seattle Genetics January 31, 2018 EX-99.5 Exhibit 99.5 LinkedIn posting by Seattle Genetics January 31, 2018 We?ve announced an agreement to acquire Cascadian Therapeutics ow.ly/i5fE30i6MpG $SGEN CEO Clay Siegall will host a conference call at 5:30am Pacific to discuss the news ow.ly/YOIW30i6t7s |
|
| January 31, 2018 |
Seattle Genetics Tweets (@SeattleGenetics), January 31, 2018 EX-99.4 Exhibit 99.4 Seattle Genetics Tweets (@SeattleGenetics), January 31, 2018 We?ve announced an agreement to acquire Cascadian Therapeutics ow.ly/i5fE30i6MpG $SGEN CEO Clay Siegall will host a conference call at 5:30am Pacific to discuss the news ow.ly/YOIW30i6t7s |
|
| January 31, 2018 |
EX-99.3 4 d525966dex993.htm EX-99.3 Exhibit 99.3 Subject: Seattle Genetics Plans to Acquires Cascadian Therapeutics, Adding a Late-Stage Breast Cancer Program to Our Growing Oncology Pipeline Date: January 31, 2018 All- Today we announced that we have signed a definitive merger agreement to acquire Cascadian Therapeutics, a clinical-stage biotechnology company with a promising late-stage breast ca |
|
| January 31, 2018 |
Investor Call and Webcast – January 31, 2018 EX-99.1 Exhibit 99.1 Investor Call and Webcast ? January 31, 2018 Seattle Genetics, Inc. (the ?Company?) has filed a registration statement (including a prospectus) and a preliminary prospectus supplement with the Securities and Exchange Commission (the ?SEC?) for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus supplement and accompan |
|
| January 31, 2018 |
SGEN / Seattle Genetics, Inc. SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 CASCADIAN THERAPEUTICS, INC. (Name of Subject Company (Issuer)) VALLEY ACQUISITION SUB, INC. a wholly owned subsidiary of SEATTLE GENETICS, INC. (Names of Filing Persons (Offerors)) COMMON S |
|
| January 31, 2018 |
A Note to Cascadian Therapeutics Employees from Clay Siegall, Seattle Genetics’ CEO EX-99.2 Exhibit 99.2 Subject: A Note to Cascadian Therapeutics Employees from Clay Siegall, Seattle Genetics? CEO Date: January 31, 2018 Dear Cascadian Therapeutics Employees, I would like to convey how excited we are about the announced agreement for Seattle Genetics to acquire Cascadian Therapeutics. The combination of our companies will enable us to partner in moving tucatinib forward, and come |
|
| January 31, 2018 |
Letter to partners and vendors EX-99.4 5 d529285dex994.htm EX-99.4 Exhibit 99.4 Letter to Cascadian Partners and Vendors [Month xx], 2018 Dear [Valued Partner], I want to personally inform you that on [DATE] we announced that Cascadian Therapeutics has agreed to be acquired by Seattle Genetics. Seattle Genetics is an emerging global multi-product biotechnology company that develops and commercializes innovative therapies for th |
|
| January 31, 2018 |
CASC / Cascadian Therapeutics, Inc. SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Cascadian Therapeutics, Inc. (Name of Subject Company) Cascadian Therapeutics, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) |
|
| January 31, 2018 |
EX-99.1 Exhibit 99.1 Cascadian Email to Employees Team, Today, we made an important announcement about the future of our company ? we announced that we have entered into an agreement with Seattle Genetics under which they will acquire Cascadian Therapeutics. You can view the press release here for further details. This agreement puts us in a much stronger position to deliver on our mission. Togeth |
|
| January 31, 2018 |
Letter to HER2CLIMB clinical investigators EX-99.3 Exhibit 99.3 [Month xx], 2018 Dear [HER2CLIMB Investigator] and Team, I want to personally inform you that on [DATE] we announced that Cascadian Therapeutics has agreed to be acquired by Seattle Genetics. Seattle Genetics is an emerging global multi-product biotechnology company that develops and commercializes innovative therapies for the treatment of cancer. Our lead product candidate, t |
|
| January 31, 2018 |
Email to temporary workers and contractors EX-99.6 Exhibit 99.6 Dear Cascadian Temp Workers and Contractors, Today, it was announced that Cascadian Therapeutics has agreed to be acquired by Seattle Genetics. Cascadian has made great progress in the last year and we believe, together, we can more fully realize the potential of tucatinib for patients with HER2+ metastatic breast cancer and potentially other cancer indications. It will remain |
|
| January 31, 2018 |
Letter to vendors and suppliers EX-99.5 6 d529285dex995.htm EX-99.5 Exhibit 99.5 [Month xx], 2018 Dear [Valued Vendor or Supplier], I hope this message finds you well. You may have heard the news that Cascadian Therapeutics has agreed to be acquired by Seattle Genetics. Seattle Genetics is an emerging global multi-product biotechnology company that develops and commercializes innovative therapies for the treatment of cancer. The |
|
| January 31, 2018 |
EX-99.2 Exhibit 99.2 All Company Meeting January 31, 2018 Proprietary and Confidential Forward-Looking Statements This presentation may contain, in addition to historical information, certain forward-looking statements, including, without limitation, statements regarding the pending acquisition of Cascadian Therapeutics, Inc. by Seattle Genetics, Inc. and its affiliates, including Valley Acquisiti |
|
| January 31, 2018 |
8-K 1 d435214d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2018 CASCADIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33882 26-0868560 (State or other jurisdiction |
|
| January 31, 2018 |
EX-2.1 2 d435214dex21.htm EX-2.1 AGREEMENT AND PLAN OF MERGER This Agreement and Plan of Merger (this “Agreement”), dated as of January 30, 2018, is among Seattle Genetics, Inc., a Delaware corporation (“Parent”), Valley Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), and Cascadian Therapeutics, Inc., a Delaware corporation (the “Company”). Cap |
|
| January 31, 2018 |
Amendment to the Bylaws of Cascadian Therapeutics, Inc. EX-3.1 3 d435214dex31.htm EX-3.1 Exhibit 3.1 Amendment to Company Bylaws AMENDMENT NO. 1 TO THE BYLAWS OF CASCADIAN THERAPEUTICS, INC. Article 9 of the Bylaws of Cascadian Therapeutics, Inc., a Delaware corporation, is hereby amended to include a new Section 9.5 as follows: “Section 9.5 Exclusive Forum. Unless the corporation consents in writing to the selection of an alternative forum, the sole a |
|
| January 31, 2018 |
EX-99.1 4 d435214dex991.htm EX-99.1 Exhibit 99.1 FOR RELEASE: Wednesday, January 31, 2018 3:30 a.m. Pacific / 6:30 a.m. Eastern Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline -Enhances Seattle Genetics’ Portfolio of Solid Tumor Programs with Potential Rapid Registrational Pathways- -Provides Global Rights to Pivotal Phase 2 Prog |
|
| January 31, 2018 |
Updated Seattle Genetics disclosure. EX-99.1 Exhibit 99.1 Throughout the information in this Exhibit 99.1, unless the context specifies or implies otherwise, the terms ?Seattle Genetics,? ?the Company,? ?we,? ?us? and ?our? refer to Seattle Genetics, Inc., a Delaware corporation, and its subsidiaries on a consolidated basis. Seattle Genetics?, and ADCETRIS? are our registered trademarks in the United States. All other trademarks or t |
|
| January 31, 2018 |
EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION The following unaudited pro forma combined financial information is presented to illustrate the estimated effects of the following transactions (together, the ?Transactions?): (i) the proposed acquisition by Seattle Genetics, Inc. (the ?Company?) of Cascadian Therapeutics, Inc. (?Cascadian?) pursuant to an all cash tender offe |
|
| January 31, 2018 |
Disclosure regarding Cascadian, including related consolidated financial statements. EX-99.3 Exhibit 99.3 Throughout the information in this Exhibit 99.3, unless the context specifies or implies otherwise, the terms ?Company,? ?Cascadian Therapeutics,? ?we,? ?us,? and ?our? refer to Cascadian Therapeutics, Inc., its predecessors, Oncothyreon Inc, and Biomira Inc., and its subsidiaries. Overview We are a clinical-stage biopharmaceutical company focused on the development of therape |
|
| January 31, 2018 |
SGEN / Seattle Genetics, Inc. 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2018 Seattle Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 0-32405 91-1874389 (State or other jurisdiction of incorporation) (Commissi |
|
| January 31, 2018 |
EX-10.1 Exhibit 10.1 BARCLAYS 745 Seventh Avenue New York, New York 10019 JPMORGAN CHASE BANK, N.A. 383 Madison Avenue New York, New York 10179 January 30, 2018 Seattle Genetics, Inc. 21823 30th Drive SE Bothell, WA 98021 Project Valley Commitment Letter $400,000,000 364-Day Term Loan Facility Ladies and Gentlemen: You have advised Barclays Bank PLC (?Barclays?) and JPMorgan Chase Bank, N.A. (?JPM |
|
| January 31, 2018 |
EX-2.1 Exhibit 2.1 Execution Copy AGREEMENT AND PLAN OF MERGER among Seattle Genetics, Inc. (Parent), Valley Acquisition Sub, Inc. (Merger Sub) and Cascadian Therapeutics, Inc. (the Company) Dated as of January 30, 2018 TABLE OF CONTENTS Page ARTICLE I THE OFFER AND THE MERGER 2 Section 1.1 The Offer 2 Section 1.2 Company Action 5 Section 1.3 The Merger 6 Section 1.4 Closing 6 Section 1.5 Ef |
|
| January 31, 2018 |
SGEN / Seattle Genetics, Inc. 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2018 SEATTLE GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-32405 91-1874389 (State or other jurisdiction of incorporation) (Commissi |
|
| January 31, 2018 |
Joint Press Release dated January 31, 2018 EX-99.1 Exhibit 99.1 FOR RELEASE: Wednesday, January 31, 2018 3:30 a.m. Pacific / 6:30 a.m. Eastern Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline -Enhances Seattle Genetics Portfolio of Solid Tumor Programs with Potential Rapid Registrational Pathways- -Provides Global Rights to Pivotal Phase 2 Program in Development for HER2- |
|
| January 16, 2018 |
CASC / Cascadian Therapeutics, Inc. ESP CORRESP CASCADIAN THERAPEUTICS, INC. 3101 Western Avenue, Suite 600 Seattle, Washington 98121 January 16, 2018 VIA EDGAR ? Acceleration Request United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Ruairi J. Regan Re: Cascadian Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-222362) filed December 29, |
|
| December 29, 2017 |
EX-4.10 Exhibit 4.10 FORM OF DEBT SECURITY [Face of Security] CASCADIAN THERAPEUTICS, INC. [If applicable, insert?FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS ?PRINCIPAL AMOUNT?), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, TH |
|
| December 29, 2017 |
EX-4.11 3 d501656dex411.htm EX-4.11 Exhibit 4.11 CASCADIAN THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1—DEFINITIONS AND INCORPORATION BY REFERENCE 5 1.1 DEFINITIONS 5 1.2. OTHER DEFINITIONS 8 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 8 1.4. RULES OF CONSTRUCTION 9 ARTICLE 2—THE SECURITIES 9 2.1. ISSUABLE IN SERIES 9 2.2. ESTABLISHMENT OF TERM |
|
| December 29, 2017 |
Statement of Computation of Ratio of Earnings to Fixed Charges EX-12.1 Exhibit 12.1 Cascadian Therapeutics Inc. and Consolidated Subsidiaries Computation of Deficiency in the Coverage of Fixed Charges by Earnings Before Fixed Charges For the Nine Months Ended September 30, Years Ended December 31, 2017 2016 2015 2014 2013 2012 (in thousands) Earnings before fixed charges: Income (loss) from continuing operations before income taxes $ (40,172 ) $ (64,613 ) $ ( |
|
| December 29, 2017 |
CASC / Cascadian Therapeutics, Inc. S-3 S-3 1 d501656ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on December 29, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cascadian Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1606174 (State or other juri |
|
| December 7, 2017 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2017 CASCADIAN THERAPEUTICS, INC. |
|
| November 8, 2017 |
EX-99.1 2 ex99-1.htm PRESS RELEASE Cascadian Therapeutics, Inc. 8-K Exhibit 99.1 Cascadian Therapeutics Reports Third Quarter 2017 Financial Results Conference Call Scheduled for Today at 4:30 p.m. ET SEATTLE, November 8, 2017 – Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2017, an |
|
| November 8, 2017 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 casc-8k110817.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2017 CASCADIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33882 26-0868560 (State or other |
|
| November 8, 2017 |
Cascadian Therapeutics, Inc. 10-Q casc-10q093017.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| August 8, 2017 |
EX-99.1 2 ex99-1.htm PRESS RELEASE Cascadian Therapeutics 8-K Exhibit 99.1 Cascadian Therapeutics Reports Second Quarter 2017 Financial Results First Patients Randomized in Western Europe and Australia in Ongoing Global HER2CLIMB Registrational Trial of Tucatinib Conference Call Scheduled for Today at 4:30 p.m. ET SEATTLE, August 8, 2017 – Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-sta |
|
| August 8, 2017 |
Cascadian Therapeutics CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2017 CASCADIAN THERAPEUTICS, INC. |
|
| August 8, 2017 |
Cascadian Therapeutics, Inc. 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33882 CASCADIAN |
|
| June 9, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2017 CASCADIAN THERAPEUTICS, INC. |
|
| June 9, 2017 |
EX-3.1 Exhibit 3.1 CASCADIAN THERAPEUTICS, INC. CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Cascadian Therapeutics, Inc. (the ?Corporation?), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: 1. The name of the corporation is Cascadian Therapeutics, Inc., and the corpora |
|
| June 8, 2017 |
S-8 As filed with the Securities and Exchange Commission on June 8, 2017 Registration No. |
|
| May 22, 2017 |
CASCADIAN THERAPEUTICS, INC. 2601 Fourth Ave., Suite 500 Seattle, Washington 98121 (206) 801-2100 May 22, 2017 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ruairi J. Regan Re: Cascadian Therapeutics, Inc. Registration Statement on Form S-3 Filed May 8, 2017 File No. 333-217773 Via EDGAR - Acceleration Request Requested Date: May 23, 2017 Requested Time: 4 |
|
| May 16, 2017 |
CORRESP 1 filename1.htm CASCADIAN THERAPEUTICS, INC. 2601 Fourth Ave., Suite 500 Seattle, Washington 98121 (206) 801-2100 May 16, 2017 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ruairi J. Regan Re: Cascadian Therapeutics, Inc. Registration Statement on Form S-3 Filed May 8, 2017 File No. 333-217773 Via EDGAR - Acceleration Request Requested Date: May 18 |
|
| May 9, 2017 |
Cascadian Therapeutics 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 9, 2017 |
EX-99.1 2 d392963dex991.htm EX-99.1 Exhibit 99.1 Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ET SEATTLE, May 9, 2017 – Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2017. “In the first quarter, we continued to buil |
|
| May 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d392963d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2017 CASCADIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33882 26-0868560 (State or other jurisdiction of in |
|
| May 8, 2017 |
Table of Contents As filed with the Securities and Exchange Commission on May 8, 2017 Registration No. |
|
| April 26, 2017 |
Cascadian Therapeutics DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Pro |
|
| April 26, 2017 |
DEF 14A 1 d374147ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 14, 2017 |
Cascadian Therapeutics PRE 14A PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 13, 2017 |
Cascadian Therapeutics Announces Changes to Board of Directors EX-99.1 Exhibit 99.1 Cascadian Therapeutics Announces Changes to Board of Directors SEATTLE, March 13, 2017 ? Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Robert W. Azelby has been appointed to the Company?s Board of Directors. Mr. Azelby is a biotechnology and pharmaceutical industry veteran. He currently serves as Executive Vice Pre |
|
| March 13, 2017 |
Cascadian Therapeutics 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2017 CASCADIAN THERAPEUTICS, INC. |
|
| March 9, 2017 |
EX-21.1 2 d323687dex211.htm EX-21.1 EXHIBIT 21.1 SUBSIDIARIES OF CASCADIAN THERAPEUTICS, INC. Name of Subsidiary Jurisdiction of Incorporation Oncothyreon Canada ULC Alberta Biomira Management, Inc. Delaware ProlX Pharmaceuticals Corporation Delaware 0811769 B.C. ULC British Columbia Oncothyreon Luxembourg s.a.r.l. Protocell Therapeutics Inc. Luxembourg Delaware |
|
| March 9, 2017 |
Cascadian Therapeutics FORM 10-K (Annual Report) Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2017 CASCADIAN THERAPEUTICS, INC. |
|
| March 9, 2017 |
Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results EX-99.1 Exhibit 99.1 Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results SEATTLE, March 9, 2017 ? Cascadian Therapeutics, Inc. (NASDAQ:CASC) today reported financial results for the fourth quarter and full year ended December 31, 2016. ?In 2016, we focused our efforts on the development of tucatinib for late-stage HER2-positive metastatic breast cancer for patients w |
|
| February 8, 2017 |
CASC / Cascadian Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment casc16a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 14740B606 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CASCADIAN THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 14740B606 (CUSIP Number) December 31, 2016 (Date of |
|
| February 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cascadian Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 682324108 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 (Name |
|
| February 3, 2017 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2017 CASCADIAN THERAPEUTICS, INC. |
|
| February 2, 2017 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 2, 2017 with respect to the shares of Common Stock of Cascadian Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) |
|
| February 2, 2017 |
SC 13D/A 1 sc13da50742202102022017.htm AMENDMENT NO. 5 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 Cascadian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par valu |
|
| February 2, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Cascadian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 14740B606 (CUSIP Num |
|
| January 27, 2017 |
Form of Series E Convertible Preferred Stock Certificate Exhibit 4.1 SEE REVERSE SIDE FOR RESTRICTIVE LEGEND(S) NUMBER PE- * * SHARES SERIES E CONVERTIBLE PREFERRED STOCK CASCADIAN THERAPEUTICS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE This Certifies That is the record holder of ( ) fully paid and nonassessable shares of Series E Convertible Preferred Stock of CASCADIAN THERAPEUTICS, INC., transferable only on the books of the said Corp |
|
| January 27, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2017 CASCADIAN THERAPEUTICS, INC. |
|
| January 27, 2017 |
EX-3.1 Exhibit 3.1 CASCADIAN THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW CASCADIAN THERAPEUTICS, INC., a Delaware corporation (the Corporation), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the DGCL) does h |
|
| January 24, 2017 |
23,182,000 Shares CASCADIAN THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 23,182,000 Shares CASCADIAN THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT January 24, 2017 COWEN AND COMPANY, LLC BARCLAYS CAPITAL INC. As Representatives of the several Underwriters c/o COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10022 Dear Sirs: 1. INTRODUCTORY. Cascadian Therapeutics, Inc. a Delaware corporation (the ?Company?), proposes to sell, p |
|
| January 24, 2017 |
Form of Registration Rights Agreement EX-10.1 Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of January , 2017, by and among Cascadian Therapeutics, Inc., a Delaware corporation (the ?Company?), and the several purchasers signatory hereto (each a ?Purchaser? and collectively, the ?Purchasers?). NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contain |
|
| January 24, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2017 CASCADIAN THERAPEUTICS, INC. |
|
| January 24, 2017 |
EX-1.2 Exhibit 1.2 1,818 Shares CASCADIAN THERAPEUTICS, INC. Series E Convertible Preferred Stock UNDERWRITING AGREEMENT January 24, 2017 COWEN AND COMPANY, LLC BARCLAYS CAPITAL INC. As Representatives of the several Underwriters c/o COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10022 Dear Sirs: 1. INTRODUCTORY. Cascadian Therapeutics, Inc. a Delaware corporation (the ?Company?), |
|
| January 24, 2017 |
EX-4.1 Exhibit 4.1 CASCADIAN THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW CASCADIAN THERAPEUTICS, INC., a Delaware corporation (the ?Corporation?), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the ?DGCL?) does h |
|
| January 24, 2017 |
Cascadian Therapeutics Prices $82.5 Million Concurrent Offerings of Common Stock and Preferred Stock EX-99.1 Exhibit 99.1 Cascadian Therapeutics Prices $82.5 Million Concurrent Offerings of Common Stock and Preferred Stock SEATTLE, January 24, 2017 ? Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the pricing of the previously announced concurrent but separate underwritten offerings of 23,182,000 shares of its common stock at a price to the |
|
| January 24, 2017 |
1,818 Shares Series E Convertible Preferred Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-201317 and 333-215675 PROSPECTUS SUPPLEMENT Dated January 24, 2017 (To Prospectus Dated January 7, 2015) 1,818 Shares Series E Convertible Preferred Stock We are offering 1,818 shares of our Series E Convertible Preferred Stock, which we refer to as our Series E Preferred Stock, and the common stock issuable from time t |
|
| January 24, 2017 |
23,182,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-201317 and 333-215675 PROSPECTUS SUPPLEMENT Dated January 24, 2017 (to Prospectus Dated January 7, 2015) 23,182,000 Shares Common Stock We are offering 23,182,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed for trading on the NASDAQ Global |
|
| January 24, 2017 |
S-3MEF As filed with the Securities and Exchange Commission on January 24, 2017 Registration No. |
|
| January 23, 2017 |
Shares Series E Convertible Preferred Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-201317 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to |
|
| January 23, 2017 |
424B5 1 d335514d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-201317 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying pros |
|
| January 23, 2017 |
Cascadian Therapeutics 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2017 CASCADIAN THERAPEUTICS, INC. |
|
| January 23, 2017 |
One Sansome Street, 30th Floor San Francisco, CA 94104 EX-17.1 Exhibit 17.1 One Sansome Street, 30th Floor San Francisco, CA 94104 January 17, 2017 Cascadian Therapeutics, Inc. 2601 Fourth Avenue, Suite 500 Seattle, Washington 98121 Attention: Julia M. Eastland, Chief Financial Officer, Vice President and Secretary Dear Ms. Eastland: Effective immediately, I hereby resign from the Board of Directors. I have a fundamental disagreement with management a |
|
| January 17, 2017 |
SC 13D/A 1 sc13da40742202102172017.htm AMENDMENT NO. 4 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Cascadian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par valu |
|
| December 7, 2016 |
EX-99.1 Exhibit 99.1 Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support Registration Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median Duration of Response (MDR) at 10 Months in Third-line Setting for Patients With and Without Brain Metastases HER2CLIMB |
|
| December 7, 2016 |
Cascadian Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2016 CASCADIAN THERAPEUTICS, INC. |
|
| November 23, 2016 |
Cascadian Therapeutics Announces Stockholders and Board of Directors Approve Reverse Stock Split EX-99.1 Exhibit 99.1 Cascadian Therapeutics Announces Stockholders and Board of Directors Approve Reverse Stock Split SEATTLE, November 23, 2016 ? Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that at a special meeting held on November 18, 2016, stockholders voted to approve a proposal authorizing the board of directors of the Company to ef |
|
| November 23, 2016 |
Cascadian Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2016 CASCADIAN THERAPEUTICS, INC. |
|
| November 23, 2016 |
EX-3.1 Exhibit 3.1 CASCADIAN THERAPEUTICS, INC. CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Cascadian Therapeutics, Inc. (the ?Corporation?), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: 1. The name of the corporation is Cascadian Therapeutics, Inc., and the corpora |
|
| November 7, 2016 |
Cascadian Therapeutics FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 7, 2016 |
Cascadian Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2016 CASCADIAN THERAPEUTICS, INC. |
|
| November 7, 2016 |
Cascadian Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update EX-99.1 Exhibit 99.1 Cascadian Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update SEATTLE, Nov. 7, 2016 ? Cascadian Therapeutics (NASDAQ: CASC), a clinical-stage biopharmaceutical company, today provided third quarter highlights and reported financial results for the quarter ended September 30, 2016. ?We continue to make strides on the clinical development fron |
|
| October 14, 2016 |
Cascadian Therapeutics DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 4, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2016 CASCADIAN THERAPEUTICS, INC. |
|
| October 4, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2016 CASCADIAN THERAPEUTICS, INC. |
|
| October 4, 2016 |
Cascadian Therapeutics PRE 14A PRE 14A 1 d174481dpre14a.htm PRE 14A Table of Contents PRELIMINARY COPY - SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confiden |
|
| October 4, 2016 |
EX-99.1 2 d251541dex991.htm EX-99.1 Exhibit 99.1 Cascadian Therapeutics Announces Proposal for Reverse Stock Split Special meeting to be held November 18, 2016 to seek stockholder approval Seattle, WA – October 4, 2016 – Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that its board of directors has approved a plan for a reverse split of the Compan |
|
| October 4, 2016 |
EX-99.1 Exhibit 99.1 Cascadian Therapeutics Announces Proposal for Reverse Stock Split Special meeting to be held November 18, 2016 to seek stockholder approval Seattle, WA ? October 4, 2016 ? Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that its board of directors has approved a plan for a reverse split of the Company?s common stock to increase |
|
| August 8, 2016 |
EX-10.5 Exhibit 10.5 2016 EQUITY INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT Unless otherwise defined herein, the terms defined in the Cascadian Therapeutics, Inc. (the “Company”) 2016 Equity Incentive Plan (the “Plan”) will have the same meanings in this Notice of Stock Option Grant and the electronic representation of this Notice of Stock Option Grant established and maintained by the Company or |
|
| August 8, 2016 |
Cascadian Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2016 CASCADIAN THERAPEUTICS, INC. |
|
| August 8, 2016 |
EX-10.7 Exhibit 10.7 2016 EQUITY INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD (NON-EMPLOYEE DIRECTOR) Unless otherwise defined herein, the terms defined in the Cascadian Therapeutics, Inc. (the “Company”) 2016 Equity Incentive Plan (the “Plan”) will have the same meanings in this Notice of Restricted Stock Unit Award and the electronic representation of this Notice of Restricted Stock Unit |
|
| August 8, 2016 |
CASC / Cascadian Therapeutics, Inc. 10-Q - Quarterly Report - FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 8, 2016 |
EX-99.1 Exhibit 99.1 Cascadian Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update Reported positive interim results from Phase 1b ?Triplet? study investigating ONT-380 in combination with trastuzumab and capecitabine Phase 2 ?HER2CLIMB? study enrolling patients SEATTLE, WA?August 8, 2016?Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical |
|
| August 8, 2016 |
EX-10.6 Exhibit 10.6 2016 EQUITY INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD (EMPLOYEE) Unless otherwise defined herein, the terms defined in the Cascadian Therapeutics, Inc. (the “Company”) 2016 Equity Incentive Plan (the “Plan”) will have the same meanings in this Notice of Restricted Stock Unit Award and the electronic representation of this Notice of Restricted Stock Unit Award establ |
|
| July 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Cascadian Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 682324108 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 (Name, |
|
| July 8, 2016 |
ONTY / Oncothyreon, Inc. / Baupost Group LLC/MA - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Cascadian Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14740B101 (CUSIP Number) June 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| June 29, 2016 |
EX-99.1 Exhibit 99.1 Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of Advanced HER2+ Metastatic Breast Cancer SEATTLE, WA?June 29, 2016?Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic breast cancer has received Fast Track designation from the U.S. Food |
|
| June 29, 2016 |
Cascadian Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2016 CASCADIAN THERAPEUTICS, INC. |
|
| June 28, 2016 |
Form of Series D Convertible Preferred Stock Certificate. EX-4.1 Exhibit 4.1 SEE REVERSE SIDE FOR RESTRICTIVE LEGEND(S) NUMBER * * SHARES PD- SERIES D CONVERTIBLE PREFERRED STOCK CASCADIAN THERAPEUTICS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE This Certifies That is the record holder of ( ) fully paid and nonassessable shares of Series D Convertible Preferred Stock of CASCADIAN THERAPEUTICS, INC., transferable only on the books of the sa |
|
| June 28, 2016 |
Cascadian Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2016 CASCADIAN THERAPEUTICS, INC. |
|
| June 28, 2016 |
EX-99.1 Exhibit 99.1 Cascadian Therapeutics Announces Exercise of Underwriters? Over- Allotment Option and Closing of $46.0 million Concurrent Offerings of Common Stock and Series D Convertible Preferred Stock Seattle, Washington ? June 28, 2016 ? Cascadian Therapeutics, Inc. (NASDAQ: CASC) today announced that it has closed the previously announced underwritten public offering of 40,250,000 share |
|
| June 28, 2016 |
EX-3.1 Exhibit 3.1 CASCADIAN THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW CASCADIAN THERAPEUTICS, INC., a Delaware corporation (the ?Corporation?), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the ?DGCL?) does h |
|
| June 27, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Cascadian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 682324108 (CUSIP Number) SPIKE L |
|
| June 23, 2016 |
EX-99.1 7 d217044dex991.htm EX-99.1 Exhibit 99.1 Cascadian Therapeutics Prices $41.8 Million Concurrent Offerings of Common Stock and Series D Convertible Preferred Stock Seattle, Washington — June 23, 2016 — Cascadian Therapeutics, Inc. (NASDAQ: CASC) today announced the pricing of the previously announced underwritten offering of 35,000,000 shares of its common stock at a price to the public of |
|
| June 23, 2016 |
EX-4.1 Exhibit 4.1 CASCADIAN THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW CASCADIAN THERAPEUTICS, INC., a Delaware corporation (the ?Corporation?), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the ?DGCL?) does h |
|
| June 23, 2016 |
FWP Filed pursuant to Rule 433 Issuer Free Writing Prospectus Registration Statement No. |
|
| June 23, 2016 |
EX-10.1 Exhibit 10.1 SUBSCRIPTION AGREEMENT Cascadian Therapeutics, Inc. 2601 Fourth Avenue, Suite 500 Seattle, Washington 98121 Ladies and Gentlemen: The undersigned (the ?Investor?) hereby confirms and agrees with you as follows: 1. This Subscription Agreement (this ?Agreement?) is made as of the date set forth below between Cascadian Therapeutics Inc., a Delaware corporation (the ?Company?) and |
|
| June 23, 2016 |
35,000,000 Shares CASCADIAN THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 35,000,000 Shares CASCADIAN THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT June 23, 2016 COWEN AND COMPANY, LLC As Representative of the several Underwriters 599 Lexington Avenue New York, New York 10022 Dear Sirs: 1. INTRODUCTORY. Cascadian Therapeutics, Inc. a Delaware corporation (the ?Company?), proposes to sell, pursuant to the terms of this Agreement, to the severa |
|
| June 23, 2016 |
35,000,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-201317 PROSPECTUS SUPPLEMENT (to Prospectus Dated January 7, 2015) 35,000,000 Shares Common Stock We are offering 35,000,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed for trading on the NASDAQ Global Market under the symbol ?CASC.? On Jun |
|
| June 23, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2016 CASCADIAN THERAPEUTICS, INC. |
|
| June 23, 2016 |
EX-1.2 Exhibit 1.2 17,250 Shares CASCADIAN THERAPEUTICS, INC. Series D Convertible Preferred Stock PLACEMENT AGENT AGREEMENT June 23, 2016 COWEN AND COMPANY, LLC As Representative of the several Placement Agents 599 Lexington Avenue New York, New York 10022 Dear Sirs: 1. INTRODUCTORY. Cascadian Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to certain purcha |
|
| June 23, 2016 |
17,250 Shares Series D Convertible Preferred Stock 424B5 1 d212948d424b5.htm FILED PURSUANT TO RULE 424(B)(5) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-201317 PROSPECTUS SUPPLEMENT (to Prospectus Dated January 7, 2015) 17,250 Shares Series D Convertible Preferred Stock We are offering 17,250 shares of our Series D Convertible Preferred Stock, which we refer to as our Series D Preferred Stock, and the common stock issu |
|
| June 23, 2016 |
Cascadian Therapeutics FORM S-8 FORM S-8 As filed with the Securities and Exchange Commission on June 23, 2016 Registration No. |
|
| June 22, 2016 |
Filed Pursuant to Rule 424(b)(5) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| June 14, 2016 |
EX-99.1 Exhibit 99.1 Cascadian Therapeutics Reports Topline ONT-380 ?Triplet? Data and Outlines Key Development Strategies Company to webcast today?s Research and Development Day at 2 pm Eastern Seattle, WA ? June 14, 2016 ? Cascadian Therapeutics (NASDAQ: CASC), a clinical-stage biopharmaceutical company, will present clinical data from the Company?s ongoing Phase 1b studies, including updated cl |
|
| June 14, 2016 |
Cascadian Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2016 CASCADIAN THERAPEUTICS, INC. |
|
| June 9, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2016 CASCADIAN THERAPEUTICS, INC. |
|
| June 9, 2016 |
Oncothyreon Announces Corporate Name Change to Cascadian Therapeutics (NASDAQ: CASC) EX-99.1 Exhibit 99.1 Oncothyreon Announces Corporate Name Change to Cascadian Therapeutics (NASDAQ: CASC) Seattle, WA ? June 8, 2016 ? Oncothyreon Inc. (NASDAQ: ONTY), a clinical-stage biopharmaceutical company, today announced that the Company is changing its name to Cascadian Therapeutics, Inc. and will trade on the NASDAQ Global Select Market under the new ticker symbol ?CASC,? effective at mar |
|
| June 9, 2016 |
EX-3.1 Exhibit 3.1 ONCOTHYREON INC. CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Oncothyreon Inc., a Delaware corporation (the ?Corporation?), hereby certifies that: 1. The name of the corporation is Oncothyreon Inc., and the corporation was originally incorporated pursuant to the General Corporation Law of the State of Delaware (the ?DGCL?) on September 7, 200 |
|
| June 2, 2016 |
ONCOTHYREON INC. SALES AGREEMENT EX-1.1 Exhibit 1.1 ONCOTHYREON INC. $50,000,000 SALES AGREEMENT June 2, 2016 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Oncothyreon Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Placement Shares. The Company agrees that, from time to time during the term of this Ag |
|
| June 2, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2016 ONCOTHYREON INC. |
|
| June 2, 2016 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-201317 PROSPECTUS SUPPLEMENT (to Prospectus Dated January 7, 2015) $50,000,000 Common Stock We have entered into a Sales Agreement, or sales agreement, with Cowen and Company, LLC (Cowen), relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the |
|
| May 19, 2016 |
Form of Executive Employment Agreement. EX-10.1 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made as of May [ ], 2016, by and between Oncothyreon Inc. (the ?Company?) and [ ] (?Executive?). R E C I T A L S WHEREAS, the Company and Executive are parties to that certain Offer Letter, dated and effective as of [ ], and as amended from time to time, pursuant to which Executive is employed |
|
| May 19, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2016 ONCOTHYREON INC. |
|
| May 9, 2016 |
Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update EX-99.1 Exhibit 99.1 Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update SEATTLE, WASHINGTON, May 9, 2016 - Oncothyreon Inc. (NASDAQ: ONTY), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the quarter ended March 31, 2016. ?During the first quarter, the Company continued to advance its portfolio of on |
|
| May 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2016 ONCOTHYREON INC. |
|
| May 9, 2016 |
CASC / Cascadian Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 9, 2016 |
MUTUAL TERMINATION AGREEMENT STC.UNM AND ONCOTHYREON INC. EX-10.8 Exhibit 10.8 MUTUAL TERMINATION AGREEMENT Between STC.UNM AND ONCOTHYREON INC. MUTUAL TERMINATION AGREEMENT (the “Agreement”) entered into effective May 5, 2016, (the “Effective Date”) between STC.UNM, a New Mexico 501(c)(3) nonprofit corporation, with its principal office at 801 University Blvd. SE, Suite 101, Albuquerque, New Mexico 87106 (hereinafter referred to as “STC”) and ONCOTHYREO |
|
| May 6, 2016 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Pro |
|
| May 6, 2016 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defi |
|
| April 19, 2016 |
Oncothyreon PRELIMINARY PROXY STATEMENT Preliminary Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 1, 2016 |
EX-10.1 Exhibit 10.1 April 1, 2016 Diana F. Hausman, M.D. c/o Oncothyreon Inc. 2601 Fourth Ave., Suite 500 Seattle, WA 98121 Re: Resignation from Oncothyreon Inc. Dear Diana: This letter agreement states the understanding and agreement between you and Oncothyreon Inc. (the ?Company?) with respect to your resignation from the Company. The agreement between you and the Company is as follows: 1. Resi |
|
| April 1, 2016 |
RELEASE You Are Advised to Consult with an Attorney Before Signing this Release of Claims EX-10.2 Exhibit 10.2 RELEASE You Are Advised to Consult with an Attorney Before Signing this Release of Claims 1. Release. In consideration of the benefits to be provided under that certain Separation Agreement between Diana F. Hausman, M.D. (Executive) and Oncothyreon Inc. (the Company), the sufficiency of which Executive acknowledges, Executive, for herself and her heirs, executors, administ |
|
| April 1, 2016 |
Oncothyreon FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2016 ONCOTHYREON INC. |
|
| March 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2016 ONCOTHYREON INC. |
|
| March 29, 2016 |
EX-10.1 2 d156047dex101.htm EX-10.1 Exhibit 10.1 March 23, 2016 Scott Myers Dear Scott: I am delighted to offer you the position of President and Chief Executive Officer of Oncothyreon, Inc. (the “Company”), effective as April 4, 2016 (the “Employment Date”). Your annualized base salary will be $600,000 per year and you will report to the Board of Directors (the “Board”) of the Company. The other |
|
| March 29, 2016 |
Form of Notice of Inducement Stock Option Grant and Inducement Stock Option Award Agreement. EX-10.2 Exhibit 10.2 NOTICE OF INDUCEMENT STOCK OPTION GRANT You (the ?Participant?) have been granted an option to purchase shares of Common Stock of the Company subject to the terms and conditions of this Notice of Stock Option Grant and the electronic representation of this Notice of Stock Option Grant established and maintained by Oncothyreon, Inc. (the ?Company?) or a third party designated b |
|
| March 29, 2016 |
Oncothyreon Appoints Scott D. Myers Chief Executive Officer EX-99.1 4 d156047dex991.htm EX-99.1 Exhibit 99.1 Oncothyreon Appoints Scott D. Myers Chief Executive Officer SEATTLE, WASHINGTON, March 29, 2016 - Oncothyreon Inc. (NASDAQ: ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products to improve the lives and outcomes of patients with cancer, today announced the appointment of Scott D. Myers as President, C |
|
| March 14, 2016 |
EX-99.1 Exhibit 99.1 Oncothyreon Reports Full Year and Fourth Quarter 2015 Financial Results & Provides Corporate Update ? Initiated Phase 2 ONT-380 Trial Based on Encouraging Combination Data ? ? $56M in Cash and Investments at December 31, 2015 ? SEATTLE, WASHINGTON, March 14, 2016 ? Oncothyreon Inc. (NASDAQ: ONTY), a clinical-stage biopharmaceutical company dedicated to the development of thera |
|
| March 14, 2016 |
THIRD AMENDMENT TO PATENT LICENSE AGREEMENT STC.UNM and ONCOTHYREON INC. EX-10.19 Exhibit 10.19 * Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. THIRD AMENDMENT TO PATENT LICENSE AGREEMENT between STC.UNM and ONCOTHYREON INC. THIS THIRD AMENDMENT TO PATENT LICENSE AGREEMENT (“Third Amendment”) is made effective as of October 13, 2015 (the “Third Amendment Effec |
|
| March 14, 2016 |
Cascadian Therapeutics 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2016 ONCOTHYREON INC. |
|
| March 14, 2016 |
CASC / Cascadian Therapeutics, Inc. 10-K - Annual Report - 10-K 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 14, 2016 |
EX-21.1 EXHIBIT 21.1 SUBSIDIARIES OF ONCOTHYREON INC. Name of Subsidiary Jurisdiction of Incorporation Oncothyreon Canada ULC Alberta Biomira Management, Inc. Delaware ProlX Pharmaceuticals Corporation Delaware Biomira B.V. Netherlands 0811769 B.C. ULC British Columbia Oncothyreon Luxembourg s.a.r.l. Protocell Therapeutics Inc. Luxembourg Delaware |
|
| March 14, 2016 |
ONCOTHYREON INC. AMENDMENT NO. 2 TO DIANA HAUSMAN OFFER LETTER EX-10.12(B) 2 d59850dex1012b.htm EX-10.12(B) Exhibit 10.12(b) ONCOTHYREON INC. AMENDMENT NO. 2 TO DIANA HAUSMAN OFFER LETTER This amendment (this “Amendment”) is made by and between Diana Hausman (“Executive”) and Oncothyreon Inc., a Delaware corporation (the “Company” and, together with Executive, hereinafter collectively referred to as the “Parties”) on December 21, 2015. WITNESSETH: WHEREAS, th |
|
| February 24, 2016 |
8-K 1 d138071d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2016 ONCOTHYREON INC. (Exact name of registrant as specified in its charter) Delaware 001-33882 26-0868560 (State or other jurisdiction of inc |
|
| February 24, 2016 |
Amended text of Section 2.8 of the Bylaws of Oncothyreon Inc.: EX-3.1 Exhibit 3.1 Amended text of Section 2.8 of the Bylaws of Oncothyreon Inc.: 2.8 VOTING The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Section 2.10 of these bylaws, subject to Section 217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section 218 (relating to voting trusts and other |
|
| February 16, 2016 |
Amendment No. 4 to SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Oncothyreon Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 682324108 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 9, 2016 |
CASC / Cascadian Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G 1 onco15in.htm CUSIP NO. 682324108 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ONCOTHYREON INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 682324108 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) |
|
| January 12, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Oncothyreon Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 682324108 (CUSIP Number) SPIKE LOY BVF PARTN |
|
| January 12, 2016 |
Exhibit 99.1 Execution Version January 11, 2016 BVF Partners L.P. Biotechnology Value Fund, L.P. Biotechnology Value Fund II, L.P. BVF Inc. One Sansome Street, 30th Floor San Francisco, CA 94104 Biotechnology Value Trading Fund OS, L.P. BVF Partners OS Ltd. PO Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Ladies and Gentlemen: In exchange for good and valuable consideration, the receip |
|
| January 11, 2016 |
ONCOTHYREON INC. RETENTION PLAN Adopted Effective January 11, 2016 EX-10.3 Exhibit 10.3 ONCOTHYREON INC. RETENTION PLAN Adopted Effective January 11, 2016 1. INTRODUCTION The purpose of this Oncothyreon, Inc. Retention Plan (this ?Plan?) is to provide specified cash retention payments to Participants in order to induce the Participants to remain employed by the Company through the Retention Date, as defined in this Plan. Capitalized terms used in this Plan shall |
|
| January 11, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2016 ONCOTHYREON INC. |
|
| January 11, 2016 |
RETIREMENT AND SEPARATION AGREEMENT EX-10.2 3 d114110dex102.htm EX-10.2 Exhibit 10.2 RETIREMENT AND SEPARATION AGREEMENT This Retirement and Separation Agreement (the “Agreement”) is entered into by and between ONCOTHYREON INC., a Delaware Corporation, (the “Company”) and ROBERT KIRKMAN, M.D. (“Executive”) (each of Executive and the Company, a “Party,” and collectively, the “Parties”). This Agreement shall become effective (the “Eff |
|
| January 11, 2016 |
EX-10.1 Exhibit 10.1 January 11, 2016 BVF Partners L.P. Biotechnology Value Fund, L.P. Biotechnology Value Fund II, L.P. BVF Inc. One Sansome Street, 30th Floor San Francisco, CA 94104 Biotechnology Value Trading Fund OS, L.P. BVF Partners OS Ltd. PO Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Ladies and Gentlemen: In exchange for good and valuable consideration, the receipt and suff |
|
| January 11, 2016 |
EX-99.1 Exhibit 99.1 Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. as Interim CEO and Expands Board with Additions of Mark Lampert and Gwen Fyfe, M.D. ? Robert L. Kirkman, M.D. to Retire as Director, President and CEO ? Seattle, January 11, 2016 ? Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve |
|
| January 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Oncothyreon Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 682324108 (CUSIP Number) SPIKE LOY BVF PARTN |
|
| December 21, 2015 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.0001 par value, of Oncothyreon Inc., a Delaware corporation. This Joint |
|
| December 21, 2015 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2015 ONCOTHYREON INC. |
|
| December 21, 2015 |
SC 13D 1 sc13d0742202112182015.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Oncothyreon Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securitie |
|
| December 8, 2015 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2015 ONCOTHYREON INC. |
|
| December 8, 2015 |
EX-99.1 Exhibit 99.1 Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without Brain Metastases at the San Antonio Breast Cancer Symposium Company to hold conference call to discuss ONT-380 data and further development plans today at 4:30 EST Seattle, December 8, 2015 ? Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the |
|
| November 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 5, 2015 |
SECOND AMENDMENT TO PATENT LICENSE AGREEMENT STC.UNM and ONCOTHYREON INC. EX-10.1 EXHIBIT 10.1 * Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. SECOND AMENDMENT TO PATENT LICENSE AGREEMENT between STC.UNM and ONCOTHYREON INC. THIS SECOND AMENDMENT TO PATENT LICENSE AGREEMENT (“Second Amendment”) is made effective as of September 15, 2015 (the “Second Amendment E |
|
| November 5, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2015 ONCOTHYREON INC. |
|
| November 5, 2015 |
EX-99.1 Exhibit 99.1 Oncothyreon Reports Third Quarter 2015 Financial Results Company to Hold Conference Call at 4:30 p.m. EST Today SEATTLE, WASHINGTON, November 5, 2015/PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the third quarter ended September 30, 2015. Net loss for the three months ended September 30, 2015 was $4.6 million, or $0.05 per basic and dilute |
|
| August 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 6)1 Oncothyreon Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 682324108 (CUSIP Number) August 14, 2015 |
|
| August 6, 2015 |
EX-99.1 Exhibit 99.1 Oncothyreon Reports Second Quarter 2015 Financial Results Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, WASHINGTON, August 6, 2015/PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the second quarter ended June 30, 2015. Net loss for the three months ended June 30, 2015 was $10.9 million, or $0.11 per basic and diluted share, |
|
| August 6, 2015 |
Cascadian Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2015 ONCOTHYREON INC. |
|
| August 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 20, 2015 |
CORRESP 1 filename1.htm July 20, 2015 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Sharon Blume, Accounting Branch Chief Jim Rosenberg, Senior Assistant Chief Accountant Jim Peklenk, Senior Staff Accountant Re: Oncothyreon Inc. Form 10-K for the Fiscal Year Ended December 31, 2014 Filed March 10, 2015 File No. |
|
| June 11, 2015 |
Cascadian Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2015 ONCOTHYREON INC. |
|
| May 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Oncothyreon Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 682324108 (CUSIP Number) May 13, 2015 (Da |
|
| May 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Oncothyreon Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 682324108 (CUSIP Number) May 13, 2015 (Da |
|
| May 14, 2015 |
ONCOTHYREON INC. SECURITIES EXCHANGE AGREEMENT EX-10.1 Exhibit 10.1 ONCOTHYREON INC. SECURITIES EXCHANGE AGREEMENT This Securities Exchange Agreement (this ?Agreement?) is made as of May 13, 2015 (the ?Effective Date?) by and between ONCOTHYREON INC., a Delaware corporation (the ?Company?), and BIOTECHNOLOGY VALUE FUND, L.P., a Delaware limited partnership, BIOTECHNOLOGY VALUE FUND II, L.P., a Delaware limited partnership, INVESTMENT 10, L.L.C |
|
| May 14, 2015 |
Cascadian Therapeutics 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2015 ONCOTHYREON INC. |
|
| May 14, 2015 |
EX-3.1 Exhibit 3.1 ONCOTHYREON INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW ONCOTHYREON INC., a Delaware corporation (the ?Corporation?), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the ?DGCL?) does hereby certify that, in a |
|
| May 14, 2015 |
Form of Series C Convertible Preferred Stock Certificate. EX-4.1 Exhibit 4.1 SEE REVERSE SIDE FOR RESTRICTIVE LEGEND(S) NUMBER PC- * * SHARES SERIES C CONVERTIBLE PREFERRED STOCK ONCOTHYREON INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE This Certifies That is the record holder of ( ) fully paid and nonassessable shares of Series C Convertible Preferred Stock of ONCOTHYREON INC., transferable only on the books of the said Corporation by the ho |
|
| May 11, 2015 |
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT EX-10.2 3 d924784dex102.htm EX-10.2 EXHIBIT 10.2 * Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. EXECUTION COPY Confidential EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT THIS EXCLUSIVE AND COLLABORATION LICENSE AGREEMENT (this “Agreement”) dated as of April 16, 2014 (the “Effective Date” |
|
| May 11, 2015 |
FIRST AMENDMENT TO PATENT LICENSE AGREEMENT STC.UNM and ONCOTHYREON INC. EX-10.1 2 d924784dex101.htm EX-10.1 EXHIBIT 10.1 * Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. FIRST AMENDMENT TO PATENT LICENSE AGREEMENT between STC.UNM and ONCOTHYREON INC. THIS FIRST AMENDMENT TO PATENT LICENSE AGREEMENT (“First Amendment”) is made as of February 2, 2015 (the “First |
|
| May 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 11, 2015 |
EX-99.1 2 d922990dex991.htm EX-99.1 Exhibit 99.1 Oncothyreon Reports First Quarter 2015 Financial Results Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, WASHINGTON, May 11, 2015/PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the first quarter ended March 31, 2015. Net loss for the three months ended March 31, 2015 was $7.9 million, or $0.08 per |
|
| May 11, 2015 |
Cascadian Therapeutics 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2015 ONCOTHYREON INC. |
|
| April 23, 2015 |
Cascadian Therapeutics FORM DEFA14A Form DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitiv |
|
| April 23, 2015 |
Cascadian Therapeutics DEFINITIVE PROXY STATEMENT Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 21, 2015 |
Cascadian Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2015 ONCOTHYREON INC. |
|
| March 10, 2015 |
Form of Stock Option Agreement under the Amended and Restated Share Option Plan. EXHIBIT 10.2 STOCK OPTION AGREEMENT STOCK OPTION AGREEMENT made as of the date day of month, . BETWEEN: ONCOTHYREON INC., a corporation, incorporated under the laws of the State of Delaware (hereinafter called the ?Company?) OF THE FIRST PART - and - Name, an employee/ director of the Company or one of its Subsidiaries or an entity controlled by the Company (hereinafter called the ?Optionee?) OF T |
|
| March 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33 |
|
| March 10, 2015 |
EX-21.1 5 d884239dex211.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES OF ONCOTHYREON INC. Name of Subsidiary Jurisdiction of Incorporation Oncothyreon Canada ULC Alberta Biomira Management, Inc. Delaware ProlX Pharmaceuticals Corporation Delaware Biomira B.V. Netherlands 0811769 B.C. ULC British Columbia Oncothyreon Luxembourg s.a.r.l. Protocell Therapeutics Inc. Luxembourg Delaware |
|
| March 10, 2015 |
Exhibit 10.26 * Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. Execution Copy LICENSE AGREEMENT This License Agreement (this “Agreement”), entered into as of December 11, 2014 (the “Effective Date”), is made by and between Array BioPharma Inc., a Delaware corporation, having offices at 320 |
|
| March 10, 2015 |
Cascadian Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2015 ONCOTHYREON INC. |
|
| March 10, 2015 |
Amended and Restated Share Option Plan. EXHIBIT 10.1 ONCOTHYREON INC. AMENDED AND RESTATED SHARE OPTION PLAN 1. PURPOSE. The purpose of this Plan is to promote the interests of the Company and its shareholders by making provision for the granting of stock options by the board of directors of the Company to selected Employees and Directors of the Company and of its Subsidiaries and to selected Service Providers for the purchase of Shares |
|
| March 10, 2015 |
S-8 As filed with the Securities and Exchange Commission on March 10, 2015 Registration No. |
|
| March 10, 2015 |
EX-99.1 Exhibit 99.1 Oncothyreon Reports Full Year and Fourth Quarter 2014 Financial Results Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, WASHINGTON, March 10, 2015/PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the year and quarter ended December 31, 2014. Net loss for the year ended December 31, 2014 was $50.0 million, or $0.64 per basic and |
|
| March 3, 2015 |
Oncothyreon Announces Appointment of Steven P. James to Board of Directors EX-99.1 Exhibit 99.1 Oncothyreon Announces Appointment of Steven P. James to Board of Directors SEATTLE, WASHINGTON, March 3, 2015 (GLOBE NEWSWIRE) - Oncothyreon Inc. (NASDAQ: ONTY) today announced the appointment of Steven P. James to its board of directors. “We are pleased to welcome Steve, with his extensive experience in the leadership of development stage biotechnology companies and business |
